A Phase I/II, Open-Label Clinical Trial to Evaluate the Efficacy and Safety of Golidocitinib As Monotherapy or in Combination with Pomalidomide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Latest Information Update: 08 Mar 2025
At a glance
- Drugs Golidocitinib (Primary) ; Pomalidomide
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 08 Mar 2025 New trial record